echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > New drug for atopic dermatitis!

    New drug for atopic dermatitis!

    • Last Update: 2022-02-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ASLAN Pharma today announced that the Phase 2b dose-ranging study (TREK-AD) evaluating eblasakimab (ASLAN004) in adult patients with moderate to severe atopic dermatitis (AD) has screened the first patient


    TREK-AD is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2b clinical study to evaluate the efficacy and safety of eblasakimab in adult patients with moderate to severe AD who are candidates for systemic therapy


    Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor alpha1 subunit (IL-13Rα1), one of the components of the type 2 receptor


    Mechanism of action of eblasakimab (ASLAN004)

    Recently, ASLAN announced positive data from a proof-of-concept study of eblasakimab


    Specifically, in the intention-to-treat (ITT) population, Week 8: The eblasakimab-treated group had a statistically significant improvement in the primary efficacy endpoint (percent change from baseline in the Eczema Area and Severity Index [EASI])61 % compared to 32% in the placebo group


    Note: The original text has been deleted

    Original source: ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.